Correction
Following the publication of our article [1], we noticed an error regarding the dosage of vitamin B12. In the manuscript, we reported that the daily dosage of vitamin B12 would be 0.4 mg, when in fact the dosage of vitamin B12 used in the B-VITAGE trial is 0.5 mg per day.
In the abstract:
The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily citalopram (20 to 40 mg) plus B12(0.4 mg), B6 (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life.
Should read
The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily citalopram (20 to 40 mg) plus B12(0.5 mg), B6 (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life.
In the "Intervention and Blinding" section:
Eligible participants will be randomly allocated to treatment with citalopram plus 400 μg vitamin B12, 2 mg folic acid and 25 mg B6 or citalopram plus placebo.
Should read
Eligible participants will be randomly allocated to treatment with citalopram plus 500 μg vitamin B12, 2 mg folic acid and 25 mg B6 or citalopram plus placebo.
Contributor Information
Andrew H Ford, Email: forda@meddent.uwa.edu.au.
Leon Flicker, Email: almeidao@meddent.uwa.edu.au.
Kieran McCaul, Email: almeidao@meddent.uwa.edu.au.
Frank van Bockxmeer, Email: almeidao@meddent.uwa.edu.au.
Sarah Hegarty, Email: almeidao@meddent.uwa.edu.au.
Varsha Hirani, Email: almeidao@meddent.uwa.edu.au.
Stephen Fenner, Email: almeidao@meddent.uwa.edu.au.
Osvaldo P Almeida, Email: osvaldo.almeida@uwa.edu.au.
References
- Ford AH, Flicker L, McCaul K, van Bockxmeer F, Hegarty S, Hirani V, Fenner S, Almeida OP. The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life. Trials. 2010;11:8. doi: 10.1186/1745-6215-11-8. [DOI] [PMC free article] [PubMed] [Google Scholar]